<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292591</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD043921</org_study_id>
    <secondary_id>5R01HD043921</secondary_id>
    <nct_id>NCT00292591</nct_id>
  </id_info>
  <brief_title>Evaluation of Vitamin D Requirements During Pregnancy</brief_title>
  <official_title>Evaluation of Vitamin D Requirements During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of vitamin D supplementation
      during pregnancy starting at the beginning of the second trimester. Mothers will be
      randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units
      per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D
      status of women regardless of their ethnicity or race.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of hypovitaminosis D in reproductive aged African-American women occurs at a
      rate of &gt; 40%. Two factors have contributed to this public health problem: an inadequate DRI
      for vitamin D and avoidance of sun exposure/use of sunscreen. This startling rate of
      hypovitaminosis D requires that the DRI for vitamin D in pregnancy be evaluated in a detailed
      manner. The Cochrane Library (2002) released a report stating that there is insufficient data
      to evaluate the effects of vitamin D supplementation during pregnancy. Recently, the safety
      of prolonged supplementation with up to 25x's DRI (10,000 IU/day) was demonstrated in
      nonpregnant adults. It is essential to determine what dose of vitamin D is required to
      eliminate hypovitaminosis D during pregnancy and provide the fetus/neonate with adequate
      vitamin D stores during development and growth, particularly in darkly pigmented individuals.
      The aim of this research proposal, then, is to determine the efficacy, effectiveness, and
      safety of maternal vitamin D supplementation (as a function of ethnicity and UV exposure) in
      the prevention of hypovitaminosis D in the pregnant mother and her fetus/neonate. We
      hypothesize that darkly pigmented mothers will require substantially higher oral
      supplementation with vitamin D to eliminate hypovitaminosis D as compared to their Caucasian
      counterparts. We propose a comprehensive clinical trial to test our hypothesis. Mothers at 12
      weeks' gestation will be randomized to one of three vitamin D treatment groups:

        1. Control, 400-,

        2. 2,000-, or

        3. 4,000 IU/day to be continued throughout pregnancy.

      Calcium and vitamin D homeostasis and skeletal remodeling in the mother will be monitored
      closely throughout the pregnancy. Bone density of the mother will be measured at 12 weeks'
      gestation and one-month postpartum. Follow-up growth and skeletal integrity assessments of
      the infant will be performed at birth, 1, 6 and 12 months stratified by infant feeding
      regime. Through these proposed studies, the prevalence of hypovitaminosis D among mothers,
      their developing fetuses and neonates, and the utility of maternal therapeutic intervention
      with vitamin D for both mother and fetus/infant will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-Hydroxyvitamin D Concentration</measure>
    <time_frame>7 months</time_frame>
    <description>Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>cholecalciferol-400 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cholecalciferol 2000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group receiving 2000 IU total vitamin D3/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cholecalciferol 4000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group receiving 4000 IU/day cholecalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol (vitamin D3)</intervention_name>
    <description>randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day</description>
    <arm_group_label>cholecalciferol-400 IU</arm_group_label>
    <arm_group_label>cholecalciferol 2000 IU</arm_group_label>
    <arm_group_label>cholecalciferol 4000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
    <arm_group_label>cholecalciferol-400 IU</arm_group_label>
    <arm_group_label>cholecalciferol 2000 IU</arm_group_label>
    <arm_group_label>cholecalciferol 4000 IU</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are within the ages of 16-45 years

          2. In good general health

          3. Less than 12 weeks pregnant (based on last menstrual period)

        Exclusion Criteria:

          1. Mothers with preexisting type I or type II diabetes

          2. Mothers with preexisting hypertension

          3. Mothers with preexisting parathyroid disease or uncontrolled thyroid disease

          4. Mothers with multiple fetuses (e.g., twins, triplets, etc.)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce W. Hollis, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol L. Wagner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna Johnson, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas C. Hulsey, Sc.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005 Feb;135(2):317-22. Review.</citation>
    <PMID>15671234</PMID>
  </reference>
  <reference>
    <citation>Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med. 2005 Feb 3;352(5):515-6; author reply 515-6.</citation>
    <PMID>15689596</PMID>
  </reference>
  <results_reference>
    <citation>Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum in: J Bone Miner Res. 2011 Dec; 26(12):3001.</citation>
    <PMID>21706518</PMID>
  </results_reference>
  <results_reference>
    <citation>Hollis BW, Wagner CL. Vitamin D requirements and supplementation during pregnancy. Curr Opin Endocrinol Diabetes Obes. 2011 Dec;18(6):371-5. doi: 10.1097/MED.0b013e32834b0040. Review.</citation>
    <PMID>21857221</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>February 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2006</study_first_posted>
  <results_first_submitted>June 28, 2016</results_first_submitted>
  <results_first_submitted_qc>June 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2016</results_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Carol Wagner</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>pregnancy</keyword>
  <keyword>bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cholecalciferol-400 IU</title>
          <description>Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="P2">
          <title>Cholecalciferol 2000 IU</title>
          <description>Experimental group receiving 2000 IU total vitamin D3/day.
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="P3">
          <title>Cholecalciferol 4000 IU</title>
          <description>Experimental group receiving 4000 IU/day cholecalciferol
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="167"/>
                <participants group_id="P3" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cholecalciferol-400 IU</title>
          <description>Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="B2">
          <title>Cholecalciferol 2000 IU</title>
          <description>Experimental group receiving 2000 IU total vitamin D3/day.
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="B3">
          <title>Cholecalciferol 4000 IU</title>
          <description>Experimental group receiving 4000 IU/day cholecalciferol
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="166"/>
            <count group_id="B2" value="167"/>
            <count group_id="B3" value="168"/>
            <count group_id="B4" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="5.6"/>
                    <measurement group_id="B2" value="26.7" spread="5.5"/>
                    <measurement group_id="B3" value="26.4" spread="5.4"/>
                    <measurement group_id="B4" value="26.5" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="168"/>
                    <measurement group_id="B4" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>25-Hydroxyvitamin D Concentration</title>
        <description>Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cholecalciferol-400 IU</title>
            <description>Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
          </group>
          <group group_id="O2">
            <title>Cholecalciferol 2000 IU</title>
            <description>Experimental group receiving 2000 IU total vitamin D3/day.
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
          </group>
          <group group_id="O3">
            <title>Cholecalciferol 4000 IU</title>
            <description>Experimental group receiving 4000 IU/day cholecalciferol
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
          </group>
        </group_list>
        <measure>
          <title>25-Hydroxyvitamin D Concentration</title>
          <description>Circulating total 25(OH)D concentration measured in serum at visit 7, one month prior to delivery</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="14.4"/>
                    <measurement group_id="O2" value="41.0" spread="14.6"/>
                    <measurement group_id="O3" value="45.7" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cholecalciferol-400 IU</title>
          <description>Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="E2">
          <title>Cholecalciferol 2000 IU</title>
          <description>Experimental group receiving 2000 IU total vitamin D3/day.
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
        <group group_id="E3">
          <title>Cholecalciferol 4000 IU</title>
          <description>Experimental group receiving 4000 IU/day cholecalciferol
cholecalciferol (vitamin D3): randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
cholecalciferol: comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy loss (miscarriage/fetal death)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Complications of Pregnancy</sub_title>
                <description>Examples include preterm birth or labor complications due to infection, pre-eclampsia, gestational diabetes, etc. (not reported separately due to small numbers)</description>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="166"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="167"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carol Wagner</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>18437922112</phone>
      <email>wagnercl@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

